When it comes to neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and certain forms of dementia, ...
7don MSN
Boosting the cell's own cleanup: New class of small molecules accelerate natural protein degradation
Proteins that are no longer needed, defective, or potentially harmful are labeled with a molecular "tag" and dismantled in ...
This article is based on a poster originally authored by Mat Calder, Ben Durham, Amy Prosser, Miguel Coelho, Aimee Blair, Jack Cobb, Marta Falcicchio, Ruben Alvarez Fernandez, Emma Ford, Alberto ...
Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 ...
In the world of protein degradation, sometimes a spanner in the works isn’t an inconvenience but the desired result. Paris-based Enodia Therapeutics has launched out of France’s Pasteur Institute and ...
The N-end rule pathway is a conserved proteolytic system that governs protein turnover by recognising specific destabilising residues at the N-terminus of substrates – so‐called N‐degrons. This ...
Therapeutics that leverage protein degradation as their primary mechanism of action appear to be a validated new therapeutic modality. The current clinical molecules are focused on degrading ...
Autophagy and lysosomal pathways orchestrate unconventional secretion of Parkinson’s disease protein
Oxidative stress induced by 6-OHDA stimulates autophagy flux, which enhances STX17-mediated autolysosome formation, leading to the degradation of autophagosomal contents. However, in response to ...
A collaboration led by CeMM, AITHYRA both in Vienna, Austria and the Max Planck Institute of Molecular Physiology in Dortmund ...
When it comes to neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and certain forms of dementia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback